^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
arlocabtagene autoleucel (BMS-986393)
i
Other names: BMS-986393, CC-95266, BMS986393, BMS 986393, CC95266, CC 95266, arlo-cel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
GPRC5D-targeted CAR-T immunotherapy
Related drugs:
2ms
QUINTESSENTIAL: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=230, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=175 --> 230
Enrollment change
|
arlocabtagene autoleucel (BMS-986393)
5ms
CC-95266-MM-001: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=180, Active, not recruiting, Juno Therapeutics, a Subsidiary of Celgene | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
Trial completion date • Trial primary completion date
|
cyclophosphamide • bendamustine • fludarabine IV • arlocabtagene autoleucel (BMS-986393)
10ms
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2) (clinicaltrials.gov)
P3, N=440, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
Enrollment open
|
lenalidomide • cyclophosphamide • Darzalex (daratumumab) • carfilzomib • pomalidomide • fludarabine IV • arlocabtagene autoleucel (BMS-986393)
11ms
QUINTESSENTIAL: Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=150, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial completion date: Jun 2030 --> Jun 2032 | Trial primary completion date: Oct 2026 --> Jun 2027
Trial completion date • Trial primary completion date
|
arlocabtagene autoleucel (BMS-986393)
1year
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2) (clinicaltrials.gov)
P3, N=440, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
New P3 trial • CAR T-Cell Therapy
|
lenalidomide • cyclophosphamide • Darzalex (daratumumab) • carfilzomib • pomalidomide • fludarabine IV • arlocabtagene autoleucel (BMS-986393)
over1year
QUINTESSENTIAL: Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=150, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
arlocabtagene autoleucel (BMS-986393)
over1year
QUINTESSENTIAL: Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P2, N=150, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
New P2 trial • CAR T-Cell Therapy
|
arlocabtagene autoleucel (BMS-986393)
almost2years
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=111, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
Enrollment open
|
alnuctamab (CC-93269) • iberdomide (CC-220) • mezigdomide (CC-92480) • arlocabtagene autoleucel (BMS-986393)
almost2years
CC-95266-MM-001: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=180, Active, not recruiting, Juno Therapeutics, a Subsidiary of Celgene | Recruiting --> Active, not recruiting
Enrollment closed
|
cyclophosphamide • bendamustine • fludarabine IV • arlocabtagene autoleucel (BMS-986393)
2years
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=111, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
New P1 trial
|
alnuctamab (CC-93269) • iberdomide (CC-220) • mezigdomide (CC-92480) • arlocabtagene autoleucel (BMS-986393)
2years
BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study (ASH 2023)
In this first-in-human study, BMS-986393 showed a manageable safety profile and deep and durable responses, including MRD negativity, at all tested dose levels, including in pts refractory to prior BCMA-directed therapies. CRS and ICANS-type neurotoxicity were mostly low-grade, with increased G ≥ 3 events at the 300 and 450 × 106 CAR T‑cell doses. On-target off-tumor TRAEs, all G1/2, occurred in a minority of pts.
P1 data • IO biomarker
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
arlocabtagene autoleucel (BMS-986393)
2years
BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study (IMW 2023)
As of data cutoff, dose escalation of BMS-986393 from 25–450 × 10⁶ CAR T cells did not exceed MTD. CRS was mostly G1/2. ICANS-type neurotoxicity was infrequent, low-grade and reversible.
P1 data • CAR T-Cell Therapy • IO biomarker
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
arlocabtagene autoleucel (BMS-986393)
Share via
